Olfr951, a member of the olfactory receptor family 1 subfamily K, plays a pivotal role in the olfactory system of Mus musculus as a G-protein-coupled receptor (GPCR). Olfactory receptors, including Olfr951, are key to the detection and transduction of odorant molecules, initiating a neuronal response that triggers the perception of smell. The structural hallmark of Olfr951, as with other GPCRs, is its 7-transmembrane domain, enabling the receptor to interact with specific odorant molecules. Upon this interaction, Olfr951 activates intracellular signaling pathways via G-protein activation. This mechanism is central to the olfactory system's ability to recognize and differentiate a vast array of odorant signals, underlining the importance of such receptors in the sense of smell. Inhibiting the function of Olfr951 entails either direct or indirect approaches. Direct inhibition would involve targeting the receptor's ligand-binding domain to obstruct the interaction with odorant molecules, thereby preventing the initiation of the G-protein-mediated signaling cascade. This requires highly specific molecular targeting to avoid off-target effects on other GPCRs. On the other hand, indirect inhibition encompasses strategies that affect the receptor's activity through modulation of related pathways or cellular processes. This can include altering membrane dynamics, receptor conformation, or interfering with post-translational modifications, all of which can impact the receptor's ability to transduce signals. Additionally, targeting downstream signaling pathways that regulate receptor desensitization, internalization, or recycling can also modulate Olfr951's responsiveness. The chemicals listed in the table represent potential indirect inhibitors, each acting through distinct mechanisms, such as cytochrome P450 enzyme inhibition, modulation of neurotransmitter receptors, or alteration of G-protein coupling efficiency.
Understanding the intricacies of Olfr951's function and inhibition is crucial for unraveling the complex mechanisms of olfactory transduction. The exploration of both direct and indirect inhibitory strategies provides valuable insights into the modulation of GPCR activity, particularly in the context of olfactory receptors. This knowledge not only advances our understanding of olfactory perception but also contributes to the broader field of GPCR research, which has significant implications in sensory biology and pharmacology. The study of inhibitors of Olfr951 and similar receptors aids in developing a comprehensive understanding of the molecular dynamics governing olfactory signaling and the potential for targeted modulation of these processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole, an antifungal agent, inhibits cytochrome P450 enzymes, affecting steroid biosynthesis. This may alter GPCR function, including olfactory receptors like Olfr951, by impacting membrane lipid composition and receptor conformation. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Labetalol, a mixed alpha/beta adrenergic antagonist, modulates GPCR signaling pathways. Its action on both alpha and beta receptors can indirectly affect the signaling of GPCRs like Olfr951. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Clozapine, an atypical antipsychotic, acts on various neurotransmitter receptors, including GPCRs. Its broad receptor interaction profile can lead to modulation of GPCR pathways, indirectly affecting Olfr951 activity in olfaction. | ||||||
Sotalol hydrochloride | 959-24-0 | sc-203699 sc-203699A | 10 mg 50 mg | $68.00 $251.00 | 3 | |
Sotalol, an antiarrhythmic agent, can influence GPCR function due to its beta-blocker properties. This can lead to indirect modulation of GPCR signaling pathways, potentially affecting Olfr951. | ||||||
Buprenorphine | 52485-79-7 | sc-507499 | 1 mL | $42.00 | ||
Buprenorphine, a partial opioid receptor antagonist, influences GPCR signaling by blocking opioid receptors. This can lead to changes in GPCR-mediated signaling cascades, potentially affecting receptors like Olfr951. | ||||||
Pantoprazole | 102625-70-7 | sc-204830 sc-204830A | 100 mg 500 mg | $89.00 $255.00 | 2 | |
Pantoprazole, a proton pump inhibitor, can indirectly modulate GPCR activity. By affecting gastric acid secretion, it impacts the histamine-mediated modulation of GPCRs, potentially affecting Olfr951 signaling. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, a non-selective beta and alpha-1 adrenergic blocker, affects GPCR signaling indirectly. By blocking these receptors, it can alter G-protein coupling in related GPCRs, potentially impacting Olfr951 function. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem, a calcium channel blocker, can influence GPCR function indirectly. By modulating calcium influx, it affects GPCR-mediated signaling, potentially impacting receptors like Olfr951. | ||||||